Gilead Sciences Inc (GIS.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
As of 12:31PM CEST. Market open.
| Previous close | 62.69 |
| Open | 62.49 |
| Bid | 62.32 x 0 |
| Ask | 62.35 x 0 |
| Day's range | 62.30 - 62.49 |
| 52-week range | 61.75 - 80.04 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
ZacksInsights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
© 2024 Yahoo. All rights reserved.